Skip Nav Destination
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
Tumor necrosis factor-α blockade for the treatment of acute GVHD
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome
Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999
Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation
Issue Archive
August 1 2004
Table of Contents
INSIDE BLOOD
BLOOD WORK
REVIEW IN TRANSLATIONAL HEMATOLOGY
CHEMOKINES
Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells
Noelia Sánchez-Sánchez,Lorena Riol-Blanco,Gonzalo de la Rosa,Amaya Puig-Kröger,Julio García-Bordas,Daniel Martín,Natividad Longo,Antonio Cuadrado,Carlos Cabañas,Angel L. Corbí,Paloma Sánchez-Mateos,José Luis Rodríguez-Fernández
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL
Clinical Trials & Observations
Michael Pfreundschuh,Lorenz Trümper,Marita Kloess,Rudolf Schmits,Alfred C. Feller,Christian Rudolph,Marcel Reiser,Dieter K. Hossfeld,Bernd Metzner,Dirk Hasenclever,Norbert Schmitz,Bertram Glass,Christian Rübe,Markus Loeffler,the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL
Clinical Trials & Observations
Michael Pfreundschuh,Lorenz Trümper,Marita Kloess,Rudolf Schmits,Alfred C. Feller,Christian Rübe,Christian Rudolph,Marcel Reiser,Dieter K. Hossfeld,Hartmut Eimermacher,Dirk Hasenclever,Norbert Schmitz,Markus Loeffler,the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
Clinical Trials & Observations
David A. Rizzieri,Gamal Akabani,Michael R. Zalutsky,R. Edward Coleman,Scott D. Metzler,James E. Bowsher,Bonnie Toaso,Elizabeth Anderson,Anand Lagoo,Steve Clayton,Charles N. Pegram,Joseph O. Moore,Jon P. Gockerman,Carlos DeCastro,Cristina Gasparetto,Nelson J. Chao,Darell D. Bigner
Tumor necrosis factor-α blockade for the treatment of acute GVHD
Clinical Trials & Observations
Daniel Couriel,Rima Saliba,Krystal Hicks,Cindy Ippoliti,Marcos de Lima,Chitra Hosing,Issa Khouri,Borje Andersson,James Gajewski,Michele Donato,Paolo Anderlini,Dimitrios P. Kontoyiannis,Agueda Cohen,Thomas Martin,Sergio Giralt,Richard Champlin
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome
Clinical Trials & Observations
Brief Report
Daniel J. Lenihan,Alvaro J. Alencar,Deborah Yang,Razelle Kurzrock,Michael J. Keating,Madeleine Duvic
HEMATOPOIESIS
Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genome-wide analysis
Wolfgang Wagner,Alexandra Ansorge,Ute Wirkner,Volker Eckstein,Christian Schwager,Jonathon Blake,Katrin Miesala,Jan Selig,Rainer Saffrich,Wilhelm Ansorge,Anthony D. Ho
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
IMMUNOBIOLOGY
Cytolytic activity and regulatory functions of inhibitory NK cell receptor–expressing T cells expanded from granulocyte colony-stimulating factor–mobilized peripheral blood mononuclear cells
Junji Tanaka,Tomomi Toubai,Yutaka Tsutsumi,Yoko Miura,Naoko Kato,Shintarou Umehara,Kaoru Kahata,Akio Mori,Nobuyasu Toyoshima,Shuichi Ota,Takahiko Kobayashi,Masanobu Kobayashi,Masaharu Kasai,Masahiro Asaka,Masahiro Imamura
IL-2–induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation
Irini Sereti,Kara B. Anthony,Hector Martinez-Wilson,Richard Lempicki,Joseph Adelsberger,Julia A. Metcalf,Claire W. Hallahan,Dean Follmann,Richard T. Davey,Joseph A. Kovacs,H. Clifford Lane
NEOPLASIA
Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions
Clinical Trials & Observations
Holger Kohlhammer,Carsten Schwaenen,Swen Wessendorf,Karlheinz Holzmann,Hans A. Kestler,Dirk Kienle,Thomas F. E. Barth,Peter Möller,German Ott,Jörg Kalla,Bernhard Radlwimmer,Armin Pscherer,Stephan Stilgenbauer,Hartmut Döhner,Peter Lichter,Martin Bentz
PHAGOCYTES
RED CELLS
TRANSPLANTATION
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
Clinical Trials & Observations
Marcos de Lima,Daniel Couriel,Peter F. Thall,Xuemei Wang,Timothy Madden,Roy Jones,Elizabeth J. Shpall,Munir Shahjahan,Betty Pierre,Sergio Giralt,Martin Korbling,James A. Russell,Richard E. Champlin,Borje S. Andersson
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
Clinical Trials & Observations
Marcos de Lima,Athanasios Anagnostopoulos,Mark Munsell,Munir Shahjahan,Naoto Ueno,Cindy Ippoliti,Borje S. Andersson,James Gajewski,Daniel Couriel,Jorge Cortes,Michele Donato,Joyce Neumann,Richard Champlin,Sergio Giralt
Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999
Clinical Trials & Observations
Charles Peters,Lawrence R. Charnas,Ye Tan,Richard S. Ziegler,Elsa G. Shapiro,Todd DeFor,Satkiran S. Grewal,Paul J. Orchard,Susan L. Abel,Anne I. Goldman,Norma K. C. Ramsay,Kathryn E. Dusenbery,Daniel J. Loes,Lawrence A. Lockman,Shunichi Kato,Patrick R. Aubourg,Hugo W. Moser,William Krivit
Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation
Clinical Trials & Observations
Ernst Holler,Gerhard Rogler,Hans Herfarth,Julia Brenmoehl,Peter Johannes Wild,Joachim Hahn,Günther Eissner,Jürgen Schölmerich,Reinhard Andreesen
CORRESPONDENCE
-
Cover Image
Cover Image
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals